The profile of urinary lipid metabolites in healthy dogs

Taiki KIDA1), Arisa YAMAZAKI1), Koji KOBAYASHI1), Tatsuuro NAKAMURA1), Takayuki NAKAGAWA2), Ryohei NISHIMURA2) and Takahisa MURATA1)*

1)Department of Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan
2)Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan

ABSTRACT. Polyunsaturated fatty acids, including arachidonic acid (AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), are converted to hundreds of lipid mediators by cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450 (CYP), or through non-enzymatic processes, and they reflect inflammatory states of the body. We comprehensively analyzed lipid metabolites in dog urine using a liquid chromatograph-mass spectrometry (LC-MS/MS) to describe their metabolic characteristics. We detected 31 AA-derived metabolites, four EPA-derived metabolites, and a DHA-derived metabolite in all urine samples. Among AA-derived metabolites, 15, 5, 3, and 8 were generated by COX, LOX, CYP, and non-enzymatic oxidation respectively. This study will be the first step to use profiles of urinary lipid metabolites for better understanding and diagnosis of canine diseases.

KEYWORDS: dog, lipid metabolite, urine

Polyunsaturated fatty acids (PUFAs) are an essential component of mammalian bodies. Besides serving as building blocks of plasma and other membranes, PUFAs and their metabolites play physiological roles as bioactive molecules. Omega-6 (n-6) and 3 (n-3) PUFAs, such as arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are converted to hundreds of lipid mediators by cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450 (CYP) or through non-enzymatic processes. Prostaglandins (PGs), thromboxanes (TXs), and leukotrienes (LTs) derived from AA have been shown to play crucial roles in human and animal diseases [4, 5, 7, 10, 16, 17].

PUFA-derived lipid metabolites are excreted in urine. Previous studies have shown that the quantity of such urinary lipid metabolites significantly changes according to physiological states and diseases. For instance, a metabolite of prostaglandin E2 (PGE2), a major proinflammatory mediator, is increased in urine of smokers [15]. It is also associated with a risk of many types of cancer in human, including colorectal, gastric, and prostate cancer [9, 11, 18]. Our group also demonstrated that the urinary level of a prostaglandin D2 (PGD2) metabolite reflects the severity of the food allergic symptoms in human and mice [8, 13]. As urine can be collected in a non-invasive and simple way, it is a convenient tool to quantify these lipid metabolites that reflect the metabolic changes of the whole organism associated with canine diseases. As the first step to such application, we performed a liquid chromatograph-mass spectrometry (LC-MS/MS)-based analysis of lipid metabolites in urine of healthy dogs to describe their metabolic characteristics.

We collected and utilized urine samples from 12 healthy dogs without any abnormality in medical checks including physical examinations, complete blood count, blood serum chemistry, urinaly test, chest radiography, and ultrasound in Anim Pet Clinic (Tokyo, Japan) under the owners’ consents. We also confirmed that these dogs did not have a history of allergy. General information on each subject is shown in the Table 1. The samples were handled and analyzed as previously described [12]. Urine samples were stored until used at −28°C for 3–7 months. Informed written consent was obtained from all the owners at admission. The collected urines were centrifuged (20,000 × g, 5 min) and the supernatant were mixed with internal standards (Table 2). After the solid phase extraction (Oasis HLB, Waters, MA, USA), the sample solutions containing lipids fractions were eluted with methanol. The sample solution (5 μl) was injected to liquid chromatography (Nexera 2, Shimadzu, Kyoto, Japan) equipped with mass spectrometer (LCMS-8060, Shimadzu).

Metabolites of AA, EPA, and DHA, totaling 117 types in each urine sample were measured with LC-MS/MS Method Package for Lipid Mediators Ver. 2 with LabSolutions software (Shimadzu), following instruction of the manufacture. Each metabolite was...
LIPID METABOLITES IN URINE OF DOGS

J. Vet. Med. Sci. 84(5): 645–647, 2022

Each lipid metabolite containing in the urine has a different stability. Therefore, a metabolite was defined as “detected” only when it was found in all samples.

Figure 1 shows metabolic pathway maps of AA, EPA, and DHA, with each node showing whether the metabolite was detected or not. In the current study, we detected 36 lipid metabolites in total. Supplementary Table 1 showed urinary lipid metabolite profile in each dog. Among them, 31 were categorized in AA-derived metabolites (Fig. 1A through 1D), 4 in EPA-derived metabolite (Fig. 1E), and 1 in DHA-derived metabolite (Fig. 1F).

AA-derived metabolites were further classified according to enzymes responsible for the metabolism, i.e., COX (15, Fig. 1A), LOX (5, Fig. 1B), CYP (3, Fig. 1C), or non-enzymatic oxidation (8, Fig. 1D). Among metabolites detected in the current study, COX-mediated AA metabolites accounted for the largest portion. Various types of PGs and TXs, and their derivatives can be useful biomarkers reflecting inflammatory states of the body. Indeed, for instance, Baltzer et al. reported that TXB2 and metabolites of prostacyclin, PGE2, and PGF2α were increased in urine of dogs following agility exercise [1].

LT is another major class of AA metabolites produced by LOX. A previous study reported that a major LOX-derived AA metabolite, leukotriene E4 (LTE4), was increased in urine of dogs and it could be a useful biomarker that indicates the severity of inflammation in chronic enteropathies [7]. In this study, we identified LTE4, its precursors (LTA4 and LTD4), its metabolites (LTF4) and many other LOX-meditated metabolites in urine of health dogs. This result suggests that these metabolites are of potential use to describe inflammatory states of the body.

In addition to COX and LOX-meditated metabolites, three types of CYP-meditated metabolites, 5,6-DHET-lactone, 14,15-DHET, and 19-HETE, were detected in all urine samples collected from several canine breeds (Table 1). Isoform composition of CYPs, their expression pattern, and catalytic activities differ between not only species but also canine breeds [2, 14]. Thus, these CYP-meditated metabolites found in this study may be useful biomarkers that describe physiological and disease states of dogs regardless of the species and breeds. Further studies with more breeds and larger sample size for each breed are required to verify this point.

### Table 1. Characteristics of individual healthy dogs

| ID | Sex | Age (year, month) | Breed | Urine collection method |
|----|-----|------------------|-------|------------------------|
| 001 | MC | 10, 4 | Toy Poodle | Spontaneous urination |
| 002 | M | 4, 2 | Maltese | Urinary catheter |
| 003 | FS | 6, 11 | Pekinese | Cystocentesis |
| 004 | FS | 1, 4 | Toy Poodle | Spontaneous urination |
| 005 | FS | 4, 8 | Toy Poodle | Cystocentesis |
| 006 | F | 3, 9 | Corgi | Spontaneous urination |
| 007 | FS | 13, 9 | Shiba | Spontaneous urination |
| 008 | FS | 8, 2 | Toy Poodle | Cystocentesis |
| 009 | FS | 11, 2 | miniature Dachshund | Cystocentesis |
| 010 | F | 12, 1 | miniature Dachshund | Cystocentesis |
| 011 | M | 4, 8 | Toy Poodle | Urinary catheter |
| 012 | FS | 8, 2 | Mix | Cystocentesis |

M, male; F, female; C, castrated; S, spayed.

### Table 2. The list of internal standards (IS)

| Name | Concentration (ng/ml) |
|------|-----------------------|
| 1 Tetranor-Prostaglandin E Metabolite-d6 (Tetranor-PGEM-d6) | 25.0 |
| 2 6-keto-Prostaglandin F1α-d4 | 25.0 |
| 3 Thromboxane B2-d4 (TXB2-d4) | 25.0 |
| 4 Prostaglandin F2α-d4 (PGF2α-d4) | 25.0 |
| 5 Prostaglandin E2-d4 (PGE2-d4) | 25.0 |
| 6 Prostaglandin D2-d4 (PGD2-d4) | 25.0 |
| 7 Leukotriene C4-d4 (LTC4-d4) | 25.0 |
| 8 Leukotriene B4-d4 (LTB4-d4) | 25.0 |
| 9 (S)-Hydroxyeicosatetraenoic Acid-d4 (5 (S)-HETE-d4) | 25.0 |
| 10 (S)-Hydroxyeicosatetraenoic Acid-d4 (12 (S)-HETE-d4) | 25.0 |
| 11 (S)-Hydroxyeicosatetraenoic Acid-d4 (15 (S)-HETE-d4) | 25.0 |
| 12 Oleoyl Ethanolamide-d4 (OEA-d4) | 0.5 |
| 13 Eicosapentaenoic Acid-d5 (EPA-d5) | 500.0 |
| 14 Docosahexaenoic Acid-d5 (DHA-d5) | 50.0 |
| 15 Arachidonic Acid-d5 (AA-d5) | 500.0 |
Fig. 1. Metabolic pathway of arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). AA (A through D), EPA (E) and DHA (F) metabolic pathways. AA metabolic pathways were further classified by responsible enzymes: cyclooxygenase (COX, A), lipoxygenase (LOX, B), cytochrome P450 (CYP, C), or enzyme-independent oxidation (D). A black-filled circle represents a lipid metabolite which was detected in the present study, while an open circle represents a metabolite which was measured but not detected. A dot represents a metabolite which was not measured in the present study. A black square represents an enzyme responsible for the oxidation.
Interestingly, we detected as many as eight non-enzymatic oxidation products of AA, called isoprostanes, including 8-iso-PGF$_{2\alpha}$ which is frequently used as an index of oxidative stress in human [3, 6]. Increasing levels of isoprostanes detected here may also reflect oxidative stress in dogs.

In this study, we also detected four COX- or LOX-mediated metabolites of EPA: TXB$_2$, PGF$_{3\alpha}$, PGD$_3$, and LXA$_4$, and an enzyme-independent oxidation product of DHA: 10,17-DiHDoHE. As EPA and DHA cannot be synthesized in the body, mammals depend on dietary food source for these n-3 fatty acids. Therefore, amount of these metabolites in urine would be greatly affected by type of food. Additional research with detailed information on food is warranted to investigate the relationship among these EPA- and DHA-derived metabolites in urine, food, and physiological states or some diseases.

Besides the lack of information on food mentioned above, there are some limitations in the present study. Firstly, we took a conservative criterion that a metabolite should be found in all samples to be considered “detected”, even though dogs with various baseline characteristics were included in this study. Therefore, we may have missed some metabolites that would be constantly detected in healthy dogs with specific breed, sex, or age range. Secondly, urine samples were obtained by different methods in the present study, namely through a catheter, by cystocentesis, or spontaneous urination. In addition, these samples were stored for different periods before the measurement. These factors may affect profile of lipid metabolites detected.

In summary, we revealed urinary lipid profiles of healthy dogs. Various AA-derived metabolites were detected, which were either COX-, LOX-, or CYP-mediated, or non-enzymatically produced. These profiles can be useful biomarkers that reflect inflammatory states of the body and help us have a better understanding of diseases. It would also be possible to apply such urinary lipid profiles to a screening test or a diagnosis tool.

**POTENTIAL CONFLICTS OF INTEREST.** All the authors have no conflicts of interest to declare.

**ACKNOWLEDGMENTS.** We would like to thank Mr. Daisuke Murotani of Anim Pet Clinic for collecting urines of dogs. This work was supported by a Grant-in-Aid from the Japan Society for the Promotion of Science, and the Terumo Life Science Foundation, Kobayashi Foundation, and Shimadzu Science Foundation.

**REFERENCES**

1. Baltzer, W. L., Firshman, A. M., Stang, B., Warnock, J. J., Gorman, E. and McKenzie, E. C. 2012. The effect of agility exercise on eicosanoid excretion, oxidant status, and plasma lactate in dogs. *BMC Vet. Res.* 8: 249. [Medline] [CrossRef]

2. Court, M. H. 2013. Canine cytochrome P-450 (CYP) pharmacogenetics. *Vet. Clin. North Am. Small Anim. Pract.* 43: 1027–1038. [Medline] [CrossRef]

3. Cracowski, J. L., Durand, T. and Bessard, G. 2002. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. *Trends Pharmacol. Sci.* 23: 360–366. [Medline] [CrossRef]

4. Ekambaram, P., Lambiv, W., Cazzolli, R., Ashton, A. W. and Honn, K. V. 2011. The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. *Cancer Metastasis Rev.* 30: 397–408. [Medline] [CrossRef]

5. Flossmann, E. and Rothwell, P. M. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. 2007. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. *Lancet* 369: 1603–1613. [Medline] [CrossRef]

6. Graille, M., Wild, P., Sauvain, J. J., Henmendinger, M., Guseva Canu, I. and Hofp, N. B. 2020. Urinary 8-isoprostane as a biomarker for oxidative stress. A systematic review and meta-analysis. *Toxicol. Lett.* 328: 19–27. [Medline] [CrossRef]

7. Im Hof, M., Schnyder, M., Hartnack, S., Stanke-Labesque, F., Luckshandger, N. and Burgenen, I. A. 2012. Urinary leukotriene E4 concentrations as a potential marker of inflammation in dogs with inflammatory bowel disease. *J. Vet. Intern. Med.* 26: 269–274. [Medline] [CrossRef]

8. Inagaki, S., Maeda, S., Naita, M., Nakamura, T., Shimosawa, T., Murata, T. and Ohyah, Y. 2018. Urinary PGDM, a prostaglandin D$_2$ metabolite, is a novel biomarker for objectively detecting allergic reactions of food allergy. *J. Allergy Clin. Immunol.* 142: 1634–1636.e10. [Medline] [CrossRef]

9. Johnson, J. C., Schmidt, C. R., Shrubsole, M. J., Bilheimer, D. D., Joshi, P. R., Morrow, J. D., Heslin, M. J., Washington, M. K., Ness, R. M., Zheng, W., Schwartz, D. A., Coffey, R. J., Beauchamp, R. D. and Merchant, N. B. 2006. Urine PGE-M: A biomarker of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. *Clin. Gastroenterol. Hepatol.* 4: 1358–1365. [Medline] [CrossRef]

10. Kawamori, T., Uchiy, N., Sugimura, T. and Wakabayashi, K. 2003. Enhancement of colon carcinogenesis by prostaglandin E2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. *Proc. Natl. Acad. Sci. USA* 108: 19802–19807. [Medline] [CrossRef]

11. Kiely, M., Milne, G. L., Minas, T. Z., Dorsey, T. H., Tang, W., Smith, C. J., Baker, F., Loffredo, C. A., Yates, C., Cook, M. B. and Ambs, S. 2021. Interleukin-1β is a potential marker of inflammation in dogs with inflammatory bowel disease. *J. Vet. Med. Sci.* 84(5): 644–647. [Medline] [CrossRef]

12. Kobayashi, Y., Nakamura, T., Kobayashi, K. and Murata, T. 2020. The profile of urinary lipid metabolites in cats. *BMC Vet. Res.* 8: 249. [Medline] [CrossRef]

13. Martinez, S. E., Andresen, M. C., Zhu, Z., Papageorgiou, I. and Court, M. H. 2020. Pharmacogenomics of poor drug metabolism in greyhounds: cytochrome P450 (CYP) 2B11 genetic variation, breed distribution, and functional characterization. *Sci. Rep.* 7: 17687. [Medline] [CrossRef]

14. McElroy, J. P., Carmella, S. G., Heskin, A. K., Tang, M. K., Murphy, S. E., Reisinger, S. A., Jensen, J. A., Hatsukami, D. K., Hecht, S. S. and Shields, P. G. 2019. Effects of cessation of cigarette smoking on eicosanoid biomarkers of inflammation and oxidative damage. *PLoS One* 14: e0218386. [Medline] [CrossRef]

15. Meik, J., Milne, G. L., Minas, T. Z., Dorsey, T. H., Tang, W., Smith, C. J., Baker, F., Loffredo, C. A., Yates, C., Cook, M. B. and Ambs, S. 2021. Urinary pge-m in men with prostate cancer. *Cancers (Basel)* 13: 4073. [Medline] [CrossRef]

16. Murata, T., Aritake, K., Matsumoto, S., Kamauchi, S., Nakagawa, T., Hori, M., Momotani, E., Urade, Y. and Ozaki, H. 2011. Prostagladin D$_2$ is a metastasis-promoting factor in lung carcinoma. *Proc. Natl. Acad. Sci. USA* 108: 19802–19807. [Medline] [CrossRef]

17. Murata, T., Lin, M. I., Aritake, K., Matsumoto, S., Narumiya, S., Ozaki, H., Urade, Y., Hori, M. and Sessa, W. C. 2008. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. *Proc. Natl. Acad. Sci. USA* 105: 20009–20014. [Medline] [CrossRef]

18. Wang, T., Cai, H., Zheng, W., Michel, A., Pawlita, M., Milne, G., Xiang, Y. B., Gao, Y. T., Li, H. L., Rothman, N., Lan, Q., Shu, X. O. and Epplein, M. 2017. A prospective study of urinary prostaglandin E2 metabolite, helicobacter pylori antibodies, and gastric cancer risk. *Clin. Infect. Dis.* 64: 1380–1386. [Medline] [CrossRef]

J. Vet. Med. Sci. 84(5): 644–647, 2022 647